Safety of Chemotherapy Regimens Containing Thioureidoiminomethylpyridinium Perchlorate in Pulmonary Tuberculosis with Multiple, Pre-Extensively and Extensively Drug Resistance
https://doi.org/10.58838/2075-1230-2025-103-3-32-38
Abstract
The objective: to evaluate safety profile when adding thioureidoiminomethylpyridinium perchlorate (Tpp) to anti-tuberculosis regimens during the intensive phase of treatment of pulmonary tuberculosis patients with MDR, pre-XDR and XDR.
Subjects and Methods. Group Tpp+ consisted of 72 patients who completed a course of anti-tuberculosis therapy containing Tpp at a daily dose of 400 mg during the intensive phase of treatment. Group Tpp-included 50 patients who completed the intensive phase of anti-tuberculosis therapy containing no Tpp.
Results. It has been confirmed that a large number of endocrine adverse reactions (AR) leading to hypothyroidism are due to inclusion of Tpp to the treatment regimen, but to a greater extent, its combination with other thyrotoxic drugs - protionamide and aminosalicylic acid. However, there was not a single case of hypothyroidism in the group where the above drugs were prescribed without Tpp. Among 72 (100%) patients who were prescribed drugs suspected of the thyrotoxic action, hypothyroidism developed in 21% of cases: when Tpp was prescribed – in 3%, when Tpp + aminosalicylic acid were prescribed – in 11%, when Tpp + prothionamide were prescribed – in 7%.
About the Authors
O. S. Ilyina
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Olga S. Ilyina, Head of Clinic no. 2
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
S. V. Smerdin
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Sergey V. Smerdin, Doctor of Medical Sciences, Professor, Head Physician, Head of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
M. A. Plekhanova
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Maria A. Plekhanova, Doctor of Medical Sciences, Deputy Head Physician for Research, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
M. V. Vershinina
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Maria V. Vershinina, Doctor of Medical Sciences, Phthisiologist, Pulmonologist, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
E. M. Desyatskova
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Elena M. Desyatskova, Physician of Statistics and Reporting Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
E. S. Nikitina
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Ekaterina S. Nikitina, Deputy Head of Clinic no. 2
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
References
1. Ershova E.S., Turik A.L., Pavlova M.V., Revyakin E.A. The effectiveness and the safety of combined tuberculosis treatment regimens using the drug Perchlozon. Methods of forecasting, prevention and elimination of adverse events. Tuberculosis and Socially Significant Diseases, 2021, vol. 9, no. 4, pp. 43-53. (In Russ.)https://doi.org/10.54921/2413-0346-2021-12-4-43-53
2. Zagdyn Z.M., Kobesov N.V., Rusakova L.I. et al. Global Tuberculosis Burden in Russia and the World as a Public Health Problem (Historical and Analytical Review) Tuberculosis and Lung Diseases, 2023, vol. 101, no. 78-88. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-5-78-88
3. Saenko S.A., Sterlikov S.A., Rusakova L.I. Predictors for loss to follow-up in MDR-TB patients. Current Problems of Health Care and Medical Statistics, 2021, no. 3, pp. 461-464. (In Russ.) https://doi.org/10.24412/2312-2935-2021-3-461-474
4. Smerdin S.V., Makarova N.Yu., Aksenova V.A. et al. Tuberkulez v Rossii v 1991–2021 gg. [Tuberculosis in Russia in 1991–2021]. Moscow, GEOTAR-Media Publ., 2025. https://doi.org/10.33029/9704-8829-4-TRF-2025-1-224
5. Starshinova A.A., Belyaeva E.N., Kudryavtsev I.V. et al. Features of the pathogen and efficacy of drug-resistant tuberculosis treatment. Translational Medicine, 2024, vol. 11, no. 5, pp. 398-406. (In Russ.) https://doi.org/10.18705/2311-4495-2024-11-5-398-406.
6. Schegertsov D.Yu., Filinyuk O.V., Buinova L.N. et al. Adverse events during treatment of patients suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 3, pp. 35-43. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-3-35-43
7. Division of Microbilogy and Infection Diseases (DMID) adult toxicitytable. Microbilogy and Infection Diseases Clinical Research Policies, Guidance and Tools. National Institute of Allergy and Infectious Diseases: Bethesda, 2007.
8. Kumar Panda U., Ra D., Swaroop Sahoo S., Kakkar R., Singh J. Interplay between tuberculosis, mental illness, and treatment compliance: an integrative literature review. Indian J. Tuberc., 2024, vol. 71, no. 3, pp. 353-357. https://doi.org/10.1016/j.ijtb.2023.10.004
9. Massud A., Syed Sulaiman S.A, Ahmad N. et al. Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: analysis from a prospective study. Front Pharmacol., 2022, no. 13, pp. 883483. https://doi.org/10.3389/fphar.2022.883483
10. Miotto P., Zhang Y., Cirillo D.M, Yam W.C. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, vol. 23, no. 12, pp. 1098-1113.
Review
For citations:
Ilyina O.S., Smerdin S.V., Plekhanova M.A., Vershinina M.V., Desyatskova E.M., Nikitina E.S. Safety of Chemotherapy Regimens Containing Thioureidoiminomethylpyridinium Perchlorate in Pulmonary Tuberculosis with Multiple, Pre-Extensively and Extensively Drug Resistance. Tuberculosis and Lung Diseases. 2025;103(3):32-38. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-3-32-38
Views:
14
Email this article 